At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
rasagiline +1 moredrug
Likely dose
rasagiline 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of BIA 9-1067 on Rasagiline Pharmacokinetics in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating rasagiline and BIA 9-1067 for Parkinson Disease. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the effect of BIA 9-1067 on rasagiline pharmacokinetics in healthy subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesFrance
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
Primary CompletionFeb 2010
Study CompletionJul 2010
First PostedFeb 2012
TodayJul 2026
First PostedFeb 14, 2012
Enrollment StartNov 1, 2009
Primary CompletionFeb 1, 2010
Study CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 14.4 years ago
Interventions
rasagilinedrug
1 mg rasagiline (single-dose)
BIA 9-1067drug
50 mg BIA 9-1067 (single-dose)